UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-0661854 (State or other jurisd ...

CORPORATE OVERVIEW MAY 2022 NASDAQ: XENE www.xenon-pharma.com Forward Looking Statement/Safe Harbor This slide presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact could be deemed forward- ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President & Chief Executive Officer Chris Kenney - Chief Medical Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Andrew Tsai - Jefferies Paul Matteis - Stifel Brian Abrahams - RBC Capital Markets Yatin Suneja - Guggenheim David Hoang - SMBC Laura Chico - Wedbush Operator Good day. Thank you for standing ...

FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Canada 98-0661854 (State or other jurisdiction of incorporation or organization) 200-3650 Gilmore Way Burnaby, British Columbia, Canada V5G 4W8 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) Registrant's telephone number, including area code ...

H XENON CORPORATE OVERVIEW M A RC H 2 0 2 2 NASDAQ: XENE www.xenon-pharma.com Forward Looking Statement/Safe Harbor This slide presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact could be ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Alex Thompson - Stifel Andrew Tsai - Jefferies Madhu Yennawar - SVB Leerink Yatin Suneja - Guggenheim Partners David Hoang - SMBC Antonia Borovina - Bloom Burton Operator Thank you for stan ...

XENON PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36687 Canada 98-0661854 (State or other jurisdictio ...

AES 2021 Symposium Summary of Results from the "X-TOLE" Study FRIDAY, DECEMBER 3, 2021 NASDAQ: XENE www.xenon-pharma.com XEN1101 Next-Gen KV7 Channel Opener ▪ Only-in-class KV7 potassium channel modulator to treat adult focal seizures ▪ Novel MOA for rational polypharmacy ▪ Designed to address limitations of first-gen KV7 modulator, ezogabine • Higher in vitro and in vivo potency • PK TID → QD • Lacks the chemical properties that could form pigmented dimers ▪ Improved seizure reduction ▪ Potential to treat ...

AES 2021 Symposium Summary of Results from the "X-TOLE" Study FRIDAY, DECEMBER 3, 2021 NASDAQ: XENE www.xenon-pharma.com XEN1101 Next-Gen KV7 Channel Opener ▪ Only-in-class KV7 potassium channel modulator to treat adult focal seizures ▪ Novel MOA for rational polypharmacy ▪ Designed to address limitations of first-gen KV7 modulator, ezogabine • Higher in vitro and in vivo potency • PK TID → QD • Lacks the chemical properties that could form pigmented dimers ▪ Improved seizure reduction ▪ Potential to treat ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Sherry Aulin – Chief Financial Officer Ian Mortimer – President and Chief Executive Officer Chris Kenney – Chief Medical Officer Chris Von Seggern – Chief Commercial Officer Conference Call Participants Andrew Tsai – Jefferies Brian Abrahams – RBC Capital Markets Marc Goodman – SVB Leerink Eddie Hickman – Guggenheim Serge Belanger – Needham and Company Operator Good day. And thank you ...